A Comparison of Silicone Hydrogel Contact Lenses: AIR OPTIX® COLORS Versus AIR OPTIX® AQUA
NCT ID: NCT01635920
Last Updated: 2014-03-28
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
258 participants
INTERVENTIONAL
2012-06-30
2012-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Comparison of AIR OPTIX® COLORS Versus FRESHLOOK® COLORBLENDS
NCT01635933
Evaluation of the Performance of AIR OPTIX® COLORS
NCT01338402
Clinical Evaluation of Two Monthly Replacement Silicone Hydrogel Contact Lenses
NCT01629693
Comparative In-Vivo Wetting Characteristics of Silicone Hydrogel Materials With Selected Lens Care Systems
NCT01699750
A Comparison of Two Color Contact Lenses in Habitual Clear Contact Lens Wearers
NCT01782482
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AIR OPTIX® COLORS
Lotrafilcon B contact lens with color worn bilaterally for a minimum of 5 days per week, 8 hours per day, in daily wear modality for 4 weeks.
Lotrafilcon B contact lens with color
Silicone hydrogel contact lens with color
AIR OPTIX® AQUA
Lotrafilcon B contact lens worn bilaterally for a minimum of 5 days per week, 8 hours per day, in daily wear modality for 4 weeks.
Lotrafilcon B contact lens
Silicone hydrogel contact lens
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lotrafilcon B contact lens with color
Silicone hydrogel contact lens with color
Lotrafilcon B contact lens
Silicone hydrogel contact lens
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Manifest cylinder less than or equal to 0.75 diopter (D) (within the previous year) in each eye.
* Successful wear of AIR OPTIX® AQUA soft contact lenses in both eyes during the past 3 months for a minimum of 5 days per week and 8 hours per day.
* Willing to sign an Informed Consent form. If under legal age of consent, legally authorized representative must also sign an Informed Consent form.
Exclusion Criteria
* Wears habitual lenses in an extended wear modality (sleeping in lenses overnight / not removing lenses on a daily basis).
* Monovision, monocular (only one eye with functional vision), or fit with only one lens.
* History of intolerance or hypersensitivity to any component of the test articles.
* Use of any over-the-counter (OTC) or prescribed topical ocular medications within previous 7 days (excluding rewetting drops).
* Moderate or severe corneal edema, corneal vascularization, corneal staining, injection, tarsal abnormalities, "other" complications, and any corneal infiltrates.
* Current or history of ocular infection, severe inflammation, or disease within previous 6 months.
* Any systemic disease that may affect the eye or be exacerbated by use of contact lenses or contact lens solutions.
* Ocular or intra-ocular surgery within the previous 12 months (excluding placement of punctal plugs).
* Use of medications contributing to dry eye or ocular irritation unless on a stable dosing regimen for a minimum of 30 days prior to study entry and able to remain on stable regimen throughout the study.
* Participation in any investigational clinical study within previous 30 days.
16 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alcon Research
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sharon Holden Thomas, O.D.
Role: STUDY_DIRECTOR
Alcon Research
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
C-12-004
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.